AMG 598's safety and tolerability, alone or with liraglutide, was assessed in obese adults.

Obesity is a complex chronic disease associated with numerous comorbidities, including type 2 diabetes, cardiovascular disease, and certain cancers. Current pharmacological treatments often have limitations in efficacy or tolerability, necessitating the development of novel therapeutic agents. Liraglutide, a GLP-1R agonist, is an established treatment for obesity, but combination therapies or new mechanisms like AMG 598 are being explored to enhance weight loss and improve patient outcomes. This study aimed to lay foundational safety data for a new investigational compound.

This was a multiple ascending dose study designed to evaluate the safety and tolerability of AMG 598 in adults with obesity. The investigational compound was administered alone or in combination with liraglutide. The study design typically involves dose escalation, with participants receiving multiple subcutaneous doses over a specified period. The primary endpoints focused on adverse events, laboratory abnormalities, and other measures of safety and tolerability. Specific doses, routes, frequencies, or durations for AMG 598 or liraglutide were not detailed in the provided abstract, nor was the exact sample size or randomization scheme.

The provided abstract outlines the main objective of this study: to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity. However, the abstract does not present any specific findings, results, or numerical data regarding the safety profile, tolerability, or efficacy of AMG 598 or the combination therapy. Therefore, no concrete outcomes, statistical significances, or quantitative measures can be reported from the given information. The study's completion status or any preliminary safety signals are not detailed in this record.